On November 5, Astera Labs, Inc. fell 5.05% in Pre-Market Trading, trading at $211.52 per share, with turnover of $8.07 million.
The move followed a strong quarterly report and above-consensus next-quarter guidance, but market caution persisted after several analysts lowered price targets following the results.
Astera Labs, Inc. reported quarterly revenue of $584.9 million, up 154% year over year, non-GAAP EPS of $1.32, non-GAAP gross margin of 72.4%, and non-GAAP operating margin of 44.7%, while Scorpio became its largest product line. Even with those beats, recent market coverage indicated the stock came under pressure as elevated pre-earnings expectations were already priced in and investors shifted focus to valuation digestion; one brokerage cut its target price to $400 from $500 while maintaining an Outperform rating.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments